MICROMERITICS 1.0

Quinn Karylle Fuentes · 28問 · 2年前

通報

問題一覧

The science and technology of small particles

Micromeritics.

any unit of matter having defined physical dimension.

Particles.

Clinically, the particle size of a drug can affect its release from dosage forms that are administered orally, parenterally, rectally and topically. (True/False)

True.

What is thw origin of micromeritics.

Greek word small and part by jm dalla valle.

Higher surface area brings about intimate contact of the drug with the dissolution fluids in vivo and increases the drug solubility and dissolution

Release and dissolution.

Higher the dissolution, faster the absorption and hence quicker and greater the drug action. (Therapeutic effect)

Absorption and drug action.

suspension and emulsion

Physical stability.

Smaller the size of the particle, better the physical stability of the dosage form owing to the Brownian motion of the particles in the dispersion.

Physical stability.

Good flow properties of granules and powders are important in the manufacturing of tablets and capsules. The distribution of particles should be uniform in terms of number and weight.

Dose uniformity.

Im particle size distribution it is important the Shape and the surface area of individual particles (True/False)

True.

Im particle size distribution it is important the size range and number or weight of particles presence to surface are (True/False)

True.

Susp, fine emulsion

0.5-10.

Upper limit of subsieve range, coarse emulsion, flocculated susp

10-50.

Lower limit of sieve range fine powder range

50-100.

Coarse powder

150-100.

Average granule

1000-3360.

use in science, medicine, technology and diagnostic test

Uniform size.

particle size standard for particle size analyzer

Diagnostic test.

sieving or sedimentation technique

N and W.

graphic (mode)

PSD.

In optical microscopy what is the particle size measurements.

0.2 micrometer to 100 nanometer.

What are the popular measurements used in optical microscopy.

Feret diameter, martin diameter and projected area diameter.

Measure the length of a line that bisects the particle image

Martin diameter.

The line may be drawn in any direction but must be in same direction for all particles

Martin diameter.

Distance between two tangent on opposite sides of the particles parallel to some fixed direction

Feret diameter.

Is the diameter of a circle with the same area as that of the particles perpendicular to the surface on which the particles rest

Projected area diameter.

What is the device use to remove the necessity of measuring the particles by visual observation

Electronic scanner.

Used to observe, record, store and retrieve particle size data.

Video recording equipment.

microcrytalline cellulose, SCMC, sodium starch glycolate and methyl cellulose

Tablet excipients.

One of the disadvantages is the Diameter is obtained from only two dimensions of particles : length and the breadth. No estimation of the depth of thickness (True/False)

True.

(Advantage or Disadvantage) Number of particles must be counted (300-500) to obtain good estimation of distribution – tedious

Disadvantage.

Presence of agglomerates and particle of more than one component may be detected

Photomicrographs.

Sieves are produced by photoetching and electroforming techniques

90-50 micrometer.

sieve loading and duration and intensity of agitation

Sieve error.

Application of ultracentrifugation to the determination of the MW of high polymer

Sedimentation.

Diameter is relative particle size equivalent to that of sphere falling

Irregular shape.

Rate in which particle size is determined by measuring the terminal settling velocity of particles thru a liquid medium in a gravitational or centrifugal environment (range 0.8- 300mm)

Sedimentation.

Pippette method also know as

Andreasen apparatus.

particle for submicron range is 0.015 – 1.1µm. (True/False)

True.

Instrument use to measure particulate contamination in parenteral solution

Royco instrument.

Contaminants are mostly found in

Filters, clothing and container seal.

Reducing in light reaching the sensor as the particles, dispersed in a liquid or gas, passes thru sensing zone range

Light energy diffraction.

fired thru an aerosolized particles spray and photograph in three dimension with a holographic camera

Laser halography.

Particles are driven into airstream will impact on a surface in its path, provided that its inertia is sufficient to overcome the drag force that tend to keep in the air stream

Cascade impact.

Cell structure.

Cell structure.

28問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

Electrolytes and non electrolytes

Electrolytes and non electrolytes

29問 • 2年前

Quinn Karylle Fuentes · 45問 · 2年前

45問 • 2年前

Quinn Karylle Fuentes · 38問 · 2年前

POST LAB (EXP 4)

POST LAB (EXP 4)

38問 • 2年前

Density and specific gravity

Density and specific gravity

Quinn Karylle Fuentes · 18問 · 2年前

FORCES OF ATTRACTION

FORCES OF ATTRACTION

18問 • 2年前

Quinn Karylle Fuentes · 63問 · 2年前

Microbial growth

Microbial growth

63問 • 2年前

Quinn Karylle Fuentes · 61問 · 2年前

Introduction.

Introduction.

61問 • 2年前

Quinn Karylle Fuentes · 97問 · 2年前

Microbial control.

Microbial control.

97問 • 2年前

Quinn Karylle Fuentes · 100問 · 2年前

States of matter

States of matter

100問 • 2年前

Quinn Karylle Fuentes · 86問 · 2年前

Introduction.

Introduction.

86問 • 2年前

Quinn Karylle Fuentes · 77問 · 2年前

Drug development.

Drug development.

77問 • 2年前

Quinn Karylle Fuentes · 9問 · 2年前

CGMP

CGMP

9問 • 2年前

Quinn Karylle Fuentes · 24問 · 2年前

Pharmaceutical ingredients.

Pharmaceutical ingredients.

24問 • 2年前

Quinn Karylle Fuentes · 43問 · 2年前

Powdered & granules

Powdered & granules

43問 • 2年前

Quinn Karylle Fuentes · 24問 · 2年前

Capsule.

Capsule.

24問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

Tablets.

Tablets.

23問 • 2年前

Quinn Karylle Fuentes · 66問 · 2年前

Calculatiom of dose

Calculatiom of dose

66問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

Postlab 5&6

Postlab 5&6

29問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

COLLIGATIVE PROPERTIES.

COLLIGATIVE PROPERTIES.

33問 • 2年前

Quinn Karylle Fuentes · 69問 · 2年前

SEMI SOLID

SEMI SOLID

69問 • 2年前

Quinn Karylle Fuentes · 60問 · 2年前

Basic immunology

Basic immunology

60問 • 2年前

Quinn Karylle Fuentes · 62問 · 2年前

Basic immunology (2)

Basic immunology (2)

62問 • 2年前

Quinn Karylle Fuentes · 44問 · 2年前

Transdermal

Transdermal

44問 • 2年前

Quinn Karylle Fuentes · 43問 · 2年前

Distribution.

Distribution.

43問 • 2年前

Quinn Karylle Fuentes · 65問 · 2年前

Infectious disease.

Infectious disease.

65問 • 2年前

Quinn Karylle Fuentes · 79問 · 2年前

Infectious diseases (2)

Infectious diseases (2)

79問 • 2年前

Gram positive ( Bacteriology)

Gram positive ( Bacteriology)

All topic. ( Compressed.)

All topic. ( Compressed.)

Quinn Karylle Fuentes · 30問 · 2年前

All topic ( Compressed)

All topic ( Compressed)

30問 • 2年前

Quinn Karylle Fuentes · 13問 · 2年前

All topics (compressed)

All topics (compressed)

13問 • 2年前

Quinn Karylle Fuentes · 28問 · 2年前

Exercise 6 ; Isotonic solution.

Exercise 6 ; Isotonic solution.

28問 • 2年前

Quinn Karylle Fuentes · 16問 · 2年前

Exercise 5 : Buffers.

Exercise 5 : Buffers.

16問 • 2年前

Quinn Karylle Fuentes · 26問 · 2年前

Exercise 7 : Factors affecting solubility.

Exercise 7 : Factors affecting solubility.

26問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

Experiment 8: Disintegration.

Experiment 8: Disintegration.

23問 • 2年前

Experiment 9 ; Interfacial phenomenon and surface tension.

Experiment 9 ; Interfacial phenomenon and surface tension.

EXP 9 : Aromatic ammonia spirit.

EXP 9 : Aromatic ammonia spirit.

EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

Quinn Karylle Fuentes · 20問 · 2年前

EXP 12: ACACIA MUCILAGE

EXP 12: ACACIA MUCILAGE

20問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

EXP13&14 : Starch and Barrium sulfate.

EXP13&14 : Starch and Barrium sulfate.

33問 • 2年前

Quinn Karylle Fuentes · 37問 · 2年前

EXP 15 : Liquid petroleum emulsion 1.0

EXP 15 : Liquid petroleum emulsion 1.0

37問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

EXP 15: Liquid petroleum emulsion 1.1

EXP 15: Liquid petroleum emulsion 1.1

23問 • 2年前

Enterobacteriaceae

Enterobacteriaceae

Quinn Karylle Fuentes · 28問 · 2年前

Enterobacteriaceae.

Enterobacteriaceae.

28問 • 2年前

Quinn Karylle Fuentes · 31問 · 2年前

LIQUID DOSAGE FORM 1.0

LIQUID DOSAGE FORM 1.0

31問 • 2年前

Quinn Karylle Fuentes · 12問 · 2年前

Liquid dosage form

Liquid dosage form

12問 • 2年前

Quinn Karylle Fuentes · 22問 · 2年前

EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

22問 • 2年前

Quinn Karylle Fuentes · 40問 · 2年前

EXP 8 : KIRBY-BAUER TECHNIQUE

EXP 8 : KIRBY-BAUER TECHNIQUE

40問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

EXP 9: STAPHYLOCOCCI

EXP 9: STAPHYLOCOCCI

29問 • 2年前

Quinn Karylle Fuentes · 41問 · 2年前

Drug incompatibilities.

Drug incompatibilities.

41問 • 2年前

Quinn Karylle Fuentes · 41問 · 2年前

Drug compatibilities.

Drug compatibilities.

41問 • 2年前

BACTERIOLOGY 3

BACTERIOLOGY 3

Quinn Karylle Fuentes · 30問 · 2年前

BACTERIOLOGY 3

BACTERIOLOGY 3

30問 • 2年前

Quinn Karylle Fuentes · 45問 · 2年前

SUSPENSION.

SUSPENSION.

45問 • 2年前

Quinn Karylle Fuentes · 40問 · 2年前

Colloidal.

Colloidal.

40問 • 2年前

Quinn Karylle Fuentes · 38問 · 2年前

BACTERIOLOGY 4 (Rickettsia)

BACTERIOLOGY 4 (Rickettsia)

38問 • 2年前

Quinn Karylle Fuentes · 44問 · 2年前

BACTERIOLOGY.

BACTERIOLOGY.

44問 • 2年前

Quinn Karylle Fuentes · 32問 · 2年前

Emulsion.

Emulsion.

32問 • 2年前

Quinn Karylle Fuentes · 42問 · 2年前

EMULSION

EMULSION

42問 • 2年前

Quinn Karylle Fuentes · 36問 · 2年前

MEDICAL RELATED PROBLEMS.

MEDICAL RELATED PROBLEMS.

36問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

MEDICATION RELATED PROBLEMS.

MEDICATION RELATED PROBLEMS.

33問 • 2年前

Quinn Karylle Fuentes · 30問 · 2年前

Mycology.

Mycology.

30問 • 2年前

Mycology 2.0

Mycology 2.0

Quinn Karylle Fuentes · 15問 · 2年前

15問 • 2年前

Quinn Karylle Fuentes · 25問 · 2年前

ppr

ppr

25問 • 2年前

Quinn Karylle Fuentes · 20問 · 2年前

MEDICAL DEVICES.

MEDICAL DEVICES.

20問 • 2年前

Quinn Karylle Fuentes · 86問 · 1年前

Pharmacokinetics. (1.0)

Pharmacokinetics. (1.0)

86問 • 1年前

Quinn Karylle Fuentes · 100問 · 1年前

Pharmacokinetics (1.1)

Pharmacokinetics (1.1)

100問 • 1年前

Quinn Karylle Fuentes · 19問 · 1年前

Pharmacokinetics (1.2)

Pharmacokinetics (1.2)

19問 • 1年前

Quinn Karylle Fuentes · 17問 · 1年前

Introduction.

Introduction.

17問 • 1年前

Quinn Karylle Fuentes · 76問 · 1年前

Introduction of biochemistry

Introduction of biochemistry

76問 • 1年前

Quinn Karylle Fuentes · 56問 · 1年前

Intro medicanal chemistry.

Intro medicanal chemistry.

56問 • 1年前

Quinn Karylle Fuentes · 75問 · 1年前

Carbohydrates

Carbohydrates

75問 • 1年前

Quinn Karylle Fuentes · 31問 · 1年前

Carbohydrates 1.1

Carbohydrates 1.1

31問 • 1年前

Quinn Karylle Fuentes · 56問 · 1年前

Detect and quality variation.

Detect and quality variation.

56問 • 1年前

Quinn Karylle Fuentes · 98問 · 1年前

INTRODUCTION

INTRODUCTION

98問 • 1年前

Quinn Karylle Fuentes · 15問 · 1年前

lab (1-2)

lab (1-2)

15問 • 1年前

Quinn Karylle Fuentes · 14問 · 1年前

lab 1-2

lab 1-2

14問 • 1年前

Quinn Karylle Fuentes · 45問 · 1年前

Pharmaceutical chemistry.

Pharmaceutical chemistry.

45問 • 1年前

Quinn Karylle Fuentes · 35問 · 1年前

Pharmaceutical chemistry 1.1

Pharmaceutical chemistry 1.1

35問 • 1年前

Quinn Karylle Fuentes · 39問 · 1年前

Unit 3.

Unit 3.

39問 • 1年前

Quinn Karylle Fuentes · 70問 · 1年前

Histamin and kinins

Histamin and kinins

70問 • 1年前

Quinn Karylle Fuentes · 45問 · 1年前

PUD.

PUD.

45問 • 1年前

Quinn Karylle Fuentes · 61問 · 1年前

61問 • 1年前

Quinn Karylle Fuentes · 67問 · 1年前

Lipids.

Lipids.

67問 • 1年前

Quinn Karylle Fuentes · 71問 · 1年前

lipids.

lipids.

71問 • 1年前

Quinn Karylle Fuentes · 93問 · 1年前

LAB ✨

LAB ✨

93問 • 1年前

Quinn Karylle Fuentes · 87問 · 1年前

Drug discovery.

Drug discovery.

87問 • 1年前

Quinn Karylle Fuentes · 13問 · 1年前

disease of lipids.

disease of lipids.

13問 • 1年前

Quinn Karylle Fuentes · 57問 · 1年前

Intro (identify structure)

Intro (identify structure)

57問 • 1年前

Quinn Karylle Fuentes · 98問 · 1年前

Carbohydrates

Carbohydrates

98問 • 1年前

Quinn Karylle Fuentes · 96問 · 1年前

Dynamic.

Dynamic.

96問 • 1年前

Quinn Karylle Fuentes · 32問 · 1年前

Unit 1

Unit 1

32問 • 1年前